1. Home
  2. ANAB vs MCB Comparison

ANAB vs MCB Comparison

Compare ANAB & MCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$51.10

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Metropolitan Bank Holding Corp.

MCB

Metropolitan Bank Holding Corp.

HOLD

Current Price

$91.40

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
MCB
Founded
2005
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
ANAB
MCB
Price
$51.10
$91.40
Analyst Decision
Buy
Buy
Analyst Count
12
3
Target Price
$71.67
$98.67
AVG Volume (30 Days)
542.3K
89.7K
Earning Date
05-08-2026
04-21-2026
Dividend Yield
N/A
1.13%
EPS Growth
91.02
11.64
EPS
N/A
2.92
Revenue
$234,603,000.00
$11,053,000.00
Revenue This Year
N/A
$37.22
Revenue Next Year
$52.14
$14.75
P/E Ratio
N/A
$30.95
Revenue Growth
157.01
N/A
52 Week Low
$17.11
$63.81
52 Week High
$73.30
$97.84

Technical Indicators

Market Signals
Indicator
ANAB
MCB
Relative Strength Index (RSI) 31.21 54.87
Support Level $43.75 $90.72
Resistance Level $51.67 $93.56
Average True Range (ATR) 2.68 2.39
MACD -0.99 -0.05
Stochastic Oscillator 5.47 52.79

Price Performance

Historical Comparison
ANAB
MCB

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

Share on Social Networks: